ETNB

89bio (ETNB)

About 89bio (ETNB)

89bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. Its product pipeline includes pegozafermin, FGF21, NASH, and SHTG. The company was founded on January 18, 2018 and is headquartered in San Francisco, CA.

Details

Daily high

$7.20

Daily low

$6.90

Price at open

$7.13

52 Week High

$16.63

52 Week Low

$5.99

Market cap

838.4M

Dividend yield

0.00%

Volume

1.4M

Avg. volume

1.0M

P/E ratio

-2.45

89bio News